Capitalization-weighted index

ALX Oncology Added to the NASDAQ Biotechnology Index

Retrieved on:

Thursday, December 17, 2020

NASDAQ, NASDAQ Biotechnology Index, Finance, Financial markets, Business, Capitalization-weighted index, NASDAQ-100

BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI).

Key Points:

BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI).
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark.
The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis.
All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

Kezar Life Sciences Added to the Nasdaq Biotechnology Index

Retrieved on:

Monday, December 14, 2020

Oncology, Health, Consumer, Religion, General Health, Clinical trials, Biotechnology, NASDAQ, NASDAQ Biotechnology Index, Finance, Financial markets, Business, Capitalization-weighted index, NASDAQ-100

(Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

Key Points:

(Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market (Nasdaq) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.
Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria.

XOMA Added to the Russell 2000® and Russell 3000® Indexes

Retrieved on:

Monday, June 29, 2020

Financial markets, Economy, Stock market, Russell 3000 Index, Russell 2000 Index, Stock market index, Capitalization-weighted index, Index, NASDAQ, Russell Indexes, Russell Microcap Index

EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000 and Russell 3000 Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 26, 2020.

Key Points:

EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000 and Russell 3000 Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 26, 2020.
The Russell 3000 Index is a market capitalization-weighted equity index that tracks the performance of the largest 3,000 U.S. stocks.
The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000 Index.
Inclusion in the Russell 2000 Index results in automatic inclusion in the appropriate growth and value style indexes.

U.S. Auto Parts Network Selected for Russell 2000 Index

Retrieved on:

Monday, June 29, 2020

As of June 26, 2020, the Russell 2000 includes U.S. Auto Parts Network (NASDAQ: PRTS), and its flagship website, CarParts.com as new additions to the index.

Key Points:

As of June 26, 2020, the Russell 2000 includes U.S. Auto Parts Network (NASDAQ: PRTS), and its flagship website, CarParts.com as new additions to the index.
The Russell 2000 Index is a capitalization-weighted stock market index maintained by FTSE Russell that benchmarks the U.S. stock market.
"We are proud to be included in the Russell 2000 Index, said Lev Peker, CEO of U.S. Auto Parts Network.
U.S. Auto Parts Network and CarParts.com are the leading online provider of aftermarket auto parts, including collision parts, engine parts, and performance parts and accessories.

FONAR Set to Join Russell 3000 and 2000 Indexes

Retrieved on:

Thursday, June 25, 2020

Russell Indexes, Financial markets, Economy, FTSE Russell, Russell 3000 Index, Stock market index, Articles, Index, Capitalization-weighted index, Frank Russell Company, Russell Microcap Index

The Russell 3000 Index is amarket-capitalization-weighted equity index that tracks the performance of the 3,000 largest U.S.-traded stocks.

Key Points:

The Russell 3000 Index is amarket-capitalization-weighted equity index that tracks the performance of the 3,000 largest U.S.-traded stocks.
Raymond V. Damadian, M.D., Founder and Chairman of FONAR stated, We believe our inclusion in the Russell indexes is a major milestone for the Company.
FTSE Russell reports that approximately $9 trillion in assets are benchmarked against Russell US Indexes.
For more information on the Russell 3000 and 2000 Indexes and the Russell indexes reconstitution, go to the Russell Reconstitution section on the FTSE Russell website.

Chiasma Added to NASDAQ Biotechnology Index

Retrieved on:

Thursday, December 19, 2019

NASDAQ, Economy, Financial markets, Economy of New York City, NASDAQ, NASDAQ Biotechnology Index, Capitalization-weighted index, Stock market, OMX, NASDAQ-100, Stock market index

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market (Nasdaq) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

Key Points:

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market (Nasdaq) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis.
All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements among other criteria.
The NASDAQ Biotechnology Index is also the basis for the iShares NASDAQ Biotechnology Index (SM) Fund.

Grayscale Investments Announces Approval of Public Quotation for Eligible Shares of Grayscale Digital Large Cap Fund

Retrieved on:

Monday, October 14, 2019

Stock market, Security, Capitalization-weighted index, Finance, Economy

New York, Oct. 14, 2019 (GLOBE NEWSWIRE) -- GrayscaleInvestments , the worlds largest digital currency asset manager, today announced that Shares of Grayscale Digital Large Cap Fund (DLC) have received approval from FINRA for public quotation under symbol: GDLCF on OTC Markets.

Key Points:

New York, Oct. 14, 2019 (GLOBE NEWSWIRE) -- GrayscaleInvestments , the worlds largest digital currency asset manager, today announced that Shares of Grayscale Digital Large Cap Fund (DLC) have received approval from FINRA for public quotation under symbol: GDLCF on OTC Markets.
Shares created through DLCs private placement become eligible to sell into the public market after a statutory one-year holding period under Rule 144 of the Securities Act.
*
There will be no trading volume in the Shares public quotation until the Shares are DTC eligible, which GDLC is expected to receive soon.
DLC provides exposure to a diverse selection of digital currencies that meet Grayscales fund construction criteria through a market capitalization-weighted portfolio (Fund Components).